Lung SBRT Motion Management (GCC 1619)
Reason given: Funding for this study is over and the PI has request closure.
Key facts
- Where
- Baltimore and Bel Air, United StatesSee the 2 sites
Where in United States
- Ummc MsgccBaltimore, United StatesNo longer taking part
- Upper Chesapeake HealthBel Air, United StatesNo longer taking part
Trial details
- Who runs it
- University of Maryland, Baltimore
- Trial code
- NCT02695680
- Record updated
- 8 May 2024
- Original description
Real-time optical surface monitoring data will be acquired from 44 human patients with primary or metastatic lung lesions during and after their 4DCT scan (standard-of-care at our institution). A patient-specific 4D model will be developed using the raw 4DCT projections time-correlated with real-time surface monitoring. In addition, before delivering each dose fraction (3 - 5 for lung SBRT), we will acquire three 15s kV fluoroscopic image acquisitions, time-correlated with optical surface monitoring. The acquisitions will be distributed over three well-spaced beam angles, e.g., every 4th angle for a 12-field plan.Read full original descriptionShow less
Modeling Respiration-induced Motion and Deformation of Tumors and Thoracic Organs for Personalized Motion Management in Lung SBRT
Real-time optical surface monitoring data will be acquired from 44 human patients with primary or metastatic lung lesions during and after their 4DCT scan (standard-of-care at our institution). A patient-specific 4D model will be developed using the raw 4DCT projections time-correlated with real-time surface monitoring. In addition, before delivering each dose fraction (3 - 5 for lung SBRT), we will acquire three 15s kV fluoroscopic image acquisitions, time-correlated with optical surface monitoring. The acquisitions will be distributed over three well-spaced beam angles, e.g., every 4th angle for a 12-field plan.
Inclusion: Eligible disease(s)/stage(s) - Patients with primary or metastatic lung lesions to be treated using stereotactic body radiotherapy (SBRT) will be eligible for this study; Allowable type and amount of prior therapy - Any types and amounts of prior therapy will be allowed for this study; Age restriction and/or gender/ethnic restrictions - Patients must be greater than or equal to 18 years of age. There are no gender or ethnic restrictions; Life expectancy restrictions - None; ECOG or Karnofsky Performance Status - Karnofsky performance status of 50 or greater; Requirements for organ and marrow function - None; Ability to understand and the willingness to sign a written informed consent document; Tumor motion > 5 mm, maximum GTV dimension < 50 mm - per guidelines established by the AAPM Task Group 7612 and RTOG 0236.13.
Exclusion: Children (age <18); Women who are pregnant or trying to get pregnant; Pain in supine position; Karnofsky performance status < 50.